GH Research (GHRS) vs Kardigan (KARD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
GH Research is the larger company by market cap ($1.40 billion vs $1.33 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GHRS | KARD |
|---|---|---|
| Share price | $20.45 | $14.20 |
| Market cap | $1.40B | $1.33B |
| 1-day change | -2.90% | +2.68% |
| YTD return | +61.02% | — |
| 1-year return | +55.28% | — |
| 5-year return | +20.29% | — |
| EPS (TTM) | $-0.99 | $-10.65 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $31.44 | $27.00 |
| 52-week low | $12.04 | $12.23 |
| Distance from 52-week high | -34.95% | -47.41% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +109.73% | +197.54% |
| Average volume | 296.90K | 483.42K |
| Shares outstanding | 68.64M | 93.50M |
| Employees | 73 | 241 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About GH Research
GHRS stock →GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression.
Health Care · Biotechnology: Pharmaceutical Preparations · 73 employees
About Kardigan
KARD stock →Kardigan, Inc. operates as a biopharmaceutical company focused on developing medicines for cardiovascular diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 241 employees
GHRS vs KARD FAQ
Which is bigger, GH Research or Kardigan?
GH Research (GHRS) is larger, with a market capitalization of $1.40B compared with $1.33B for Kardigan (KARD).
Are GH Research and Kardigan in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.